MYCN and neuroblastoma: SFN was selected through a candidate gene approach and validated in a retrospective study specifically focused on high risk stage 4 patients [8], [10], while the PCDHB cluster was identified by MS-RDA, a subtractive genome-wide analysis conducted between MYCN amplified NB cell lines and primary tumors with good prognosis [14].